New drug ANXV aims to save sight in diabetic eye disease and vein blockages
Disease control
Recruiting now
This early study tests a new drug, ANXV, in 12 adults with diabetic retinopathy or retinal vein occlusion. Participants receive five daily infusions over 4 months to check safety and whether it improves vision. The goal is to find the right dose for larger studies.
Phase: PHASE2 • Sponsor: Annexin Pharmaceuticals AB • Aim: Disease control
Last updated May 17, 2026 17:09 UTC